Lipid-Lowering Therapy and Apheresis: Indications and Outcomes
Lipid (mg/dL) MDF (%) HELP (%) DALI (%) DSA (%) IA (%) LDL-C 56–62 55–61 53–76 49–75 62–69 Triglycerides 37–49 20–53 29–40 26–60 34–49 HDL-C 25–42 5–17 5–29 4–17 9–27…
Statins and Nutraceuticals/Functional Food: Could They Be Combined?
Fig. 11.1 Mechanism of action of the main lipid-lowering nutraceuticals More clinical research is needed to clarify the potential role in therapy of some interesting nutraceuticals with strong preclinical evidence…
Statins and Fibrates: Should They Be Recommended?
(1) Department of Hypertension, Medical University of Lodz, Lodz, Poland (2) Department of Clinical Biochemistry (Vascular Disease Prevention Clinics), Royal Free Hospital Campus, University College London Medical School, University College…
Statins and Niacin: The End of Residual Risk Therapy?
Trial Study population Dose of co-administered drug(s) Duration (median) Primary endpoint Results AIM-HIGH [12] n = 3414 Aged > 45 years, established CVD (documented stable CAD, cerebrovascular or carotid disease, or PAD)…
Statins and Mipomersen: Mechanisms of Action and Patient Tolerability
Fig. 7.1 Mechanism of action of statin and mipomersen. (a) Mipomersen specifically binds the apoB mRNA sequence to provide a substrate for RNase H, which hydrolyses the apoB mRNA strand…
